Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Special Emphasis Notice: AHRQ Announces Interest in Health Services Research to Advance Health and Healthcare Equity

National Institutes of Health

The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality’s (AHRQ) strong and continued interest in receiving applications that advance the goal of achieving equity in healthcare delivery in the United States.

AHRQ is committed to supporting healthcare delivery systems and health professionals in their efforts to transform care to be more equitable by producing evidence and supporting the development and testing of measures, interventions, and tools to ensure every person has the opportunity to attain their full potential for health and well-being.

Inequities in health outcomes are deeply rooted in historic injustices that exist across all aspects of society, including the delivery of healthcare. COVID-19 has underscored the link between social determinants and inequities in healthcare and moreover highlighted the central issue of addressing structural and systemic inequities that continue to contribute to avoidable disparities in health outcomes and health care delivery.

This SEN conveys AHRQ’s continued interest in supporting health services research to fill important gaps in scientific evidence through innovative study designs and use of collaborative methods. Applications should demonstrate meaningful engagement with diverse stakeholders and representatives from target communities, ensuring that target patient population voices are heard throughout the research process, and co-creation and co-learning is prioritized.

Inclusion of a conceptual framework is encouraged to demonstrate how research objectives center health equity and focus on addressing health disparities as a foundational element across the application. AHRQ is also interested in applications that propose to use the latest dissemination and implementation science to evaluate evidence-based interventions aimed at advancing health and healthcare equity.

Applicants should explicitly state in their cover letter and project summary of their grant application that their application is responsive to this SEN by including the title and number of this SEN NOT-HS-23-013. Applications responding to this SEN should be submitted in accordance with regular application receipt dates identified in the respective funding announcement and will be reviewed by AHRQ standing study sections. This SEN supersedes the NOT-HS-21-014 .

NOT-HS-23-013

Specialties

Medical

Medical - Translational

Medical - Clinical Science

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type:

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity